Vaccination against cocaine using a modifiable dendrimer nanoparticle platform

Lowell, Jeffrey A.; Dikici, Emre; Joshi, Priti; Landgraf, Ralf; Lemmon, Vance; Daunert, Sylvia; Izenwasser, Sari; Daftarian, Pirouz

doi:10.1016/j.vaccine.2020.10.041

Cited by 7 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…into mice with an adjuvant, forming the GNE -PDD vaccine (Table ). Advantages of this GNE -PDD vaccine included the ability to tailor the hapten employed, leading to versatility for vaccine development for other illicit substances. The PDD-modified carrier has been used to deliver and target cargo to antigen-presenting cells for cancer, anti-fungal medication, and infectious diseases (e.g., Leishmaniasis). , Interestingly, following immunization of mice, the GNE -PDD vaccine co-administered with adjuvants (CpG, Pam3CSK4, MPLA, and/or 1% alhydrogel) demonstrated a strong, rapid, and robust induction of anti-cocaine antibodies.…”

Section: Anti-cocaine Vaccinesmentioning

confidence: 99%

“…into mice with an adjuvant, forming the GNE-PDD vaccine (Table 1). 46 Advantages of this GNE-PDD vaccine included the ability to tailor the hapten employed, leading to versatility for vaccine development for other illicit substances. The PDD-modified carrier has been used to deliver and target cargo to antigen-presenting cells for cancer, antifungal medication, and infectious diseases (e.g., Leishmaniasis).…”

Section: Pre-clinical Advances Inmentioning

confidence: 99%

See 1 more Smart Citation

Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?

Stephenson

Tóth

2023

J. Med. Chem.

View full text Add to dashboard Cite

Cocaine is one of the oldest and most widely used illicit drugs in the world and is responsible for major worldwide medical and social problems. Drug addiction is a disease state where the body relies on a substance for normal functioning and develops a physical dependence leading to compulsive and repetitive use despite negative consequences to the user's health, mental state, or social life. The primary driver for the development of anti-cocaine vaccines has been the failure to develop effective pharmacological treatments to combat cocaine dependence. Despite several decades of research, no approved pharmacological treatments for cocaine dependence are available to assist addicts to overcome cocaine withdrawal or to prevent drug relapse. This Perspective highlights the challenges associated with anti-cocaine vaccines, including the current state of anti-cocaine vaccines and catalytic antibody research to aid in the fight against cocaine addiction.

show abstract

Section: Anti-cocaine Vaccinesmentioning

confidence: 99%

Section: Pre-clinical Advances Inmentioning

confidence: 99%

Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?

Stephenson

Tóth

2023

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…However, because cocaine has poor immunogenic properties, improved strategies are needed ensure a robust and sustained anti-cocaine antibody response. By conjugating a cocaine analog to a nanoparticle carrier with major histocompatibility complex (MHC) II-binding moieties, researchers were able to generate a prompt, persistent, and high-affinity anti-cocaine antibody response in animals [ 104 ]. Using this nanoparticle approach, brain levels of cocaine were reduced by 80% in mice, and in behavioral studies, conditioned place preference for cocaine was significantly attenuated in nanoparticle-treated mice.…”

Section: Nanoparticle-based Treatments For Sudmentioning

confidence: 99%

Nanoparticle delivery systems for substance use disorder

Kasina

Mownn

Bahal

et al. 2022

Neuropsychopharmacol.

View full text Add to dashboard Cite

Innovative breakthroughs in nanotechnology are having a substantial impact in healthcare, especially for brain diseases where effective therapeutic delivery systems are desperately needed. Nanoparticle delivery systems offer an unmatched ability of not only conveying a diverse array of diagnostic and therapeutic agents across complex biological barriers, but also possess the ability to transport payloads to targeted cell types over a sustained period. In substance use disorder (SUD), many therapeutic targets have been identified in preclinical studies, yet few of these findings have been translated to effective clinical treatments. The lack of success is, in part, due to the significant challenge of delivering novel therapies to the brain and specific brain cells. In this review, we evaluate the potential approaches and limitations of nanotherapeutic brain delivery systems. We also highlight the examples of promising strategies and future directions of nanocarrier-based treatments for SUD.

show abstract

“…Currently, there are various models of cocaine vaccines, 16–26 which have shown relative success in preventing cocaine from crossing the BB 27–30 and in reducing self-administration, 24 , 27–29 , 31–34 place-preference, 35 and locomotor activity, 18 , 19 , 21 , 25 , 29 , 36–40 induced by cocaine, in rodents. However, the efficacy of anti-cocaine vaccines has been largely limited by the modest levels of vaccine-induced antibodies and/or by a variable production of anti-cocaine antibodies, when evaluated in primates.…”

Section: Introductionmentioning

confidence: 99%

COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats

Barbosa-Méndez,

Matus-Ortega,

Hernandez-Miramontes

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vaccination active, promising alternative immunological strategy to treat of CUD. Various models of cocaine vaccines have been evaluated in animals and humans with relative success. In this sense, it is necessary to improve or optimize the cocaine vaccines already evaluated. Our laboratory previously reported the efficacy of the tetanus toxoid-conjugated morphine vaccine (M 6 -TT). The M 6 -TT vaccine can generate high titers of antibodies and reduce heroin-induced behavioral effects in rodents. So, it would be plausible to assume that if we modify the M 6 -TT vaccine by changing the hapten and maintaining the rest of the structural elements of the vaccine, we will maintain the properties of the M 6 -TT vaccine (high antibody titers). The objective of this study was to determine whether the antibodies generated by a tetanus toxoid-conjugated cocaine vaccine (COC-TT) can recognize and capture cocaine and decrease the cocaine-induced reinforcing effects. Male Wistar rats were immunized with the COC-TT. A solid-phase antibody-capture ELISA was used to monitor antibody titer responses after each booster dose in vaccinated animals. The study used cocaine self-administration and place-preference testing to evaluate the cocaine-reinforcing effects. The COC-TT vaccine could generate high levels of anti-cocaine antibodies. The antibodies reduced the cocaine self-administration and cocaine place preference. In addition, they decreased the cocaine-induced Fos protein expression. These findings suggest that the COC-TT vaccine generates a robust immunogenic response capable of reducing the reinforcing effects of cocaine, which supports its possible future use in clinical trials in patients with CUD.

show abstract

Vaccination against cocaine using a modifiable dendrimer nanoparticle platform

Cited by 7 publications

References 51 publications

Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?

Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?

Nanoparticle delivery systems for substance use disorder

COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats

Contact Info

Product

Resources

About